|
|
News Breaks | | | | July 29, 2012 | | 10:23 EDT |  | ABT | Abbott Laboratories CEO Miles White is just getting started, Barron's says
Abbott Laboratories' (ABT) revenue has grown fourfold on CEO Mike White's watch. EPS are up almost as much, to a projected $5.05 this year, quite a feat in an industry in which mergers have driven revenue growth but diluted EPS, Barron's contends. White's perseverance has paid off for shareholders. Since he took over as CEO, Abbott's shares have risen an average of 5.3% annually with dividends, compared with 2.6% for the S&P's 500 and 1.5% for the S&P 500 Pharmaceuticals index. Since the announcement of the proprietary drug business spin-off in October 2011, the shares are up 24%. Cowen's Ian Sanderson thinks the combined companies are worth as much as $67 a share. Longer-term, Abbott's revenue could increase at a substantially faster clip. Sales of nutritionals alone, the company Sanderson said, could climb to nearly $10B in 2015 from $6B currently, driven by growth in emerging markets. Reference Link | |
|
News For ABT From The Last 14 Days Check below for free stories on ABT the last two weeks. |
|
|
| May 21, 2013 | | 08:03 EDT |  | ABT | Abbott announces CE Mark for coronary drug eluting stent
 Subscribe for More Information | | | May 20, 2013 | | 10:11 EDT |  | ABT | On The Fly: Analyst Upgrade Summary
Subscribe for More Information | | | 06:01 EDT | | ABT | Abbott upgraded to Buy from Neutral at Goldman
Goldman upgraded Abbott to reflect accelerating growth driven by emerging markets, better growth and product mix, new product launches, and market share gains. Price target raised to $44 from $38. | | | May 9, 2013 | | 07:04 EDT | | ABT | Abbott announces CE Mark for A1c test
Subscribe for More Information | |
|
|
|
|
|
|
